BID | 1.61 | ASK | 1.68 | ||
Open | 1.69 | Previous Close | 1.70 | ||
Pre-Market | - | After-Market | 1.73 | ||
- - | 0.08 4.85% |
Target Price | 10.67 | Analyst Rating | Moderate Buy 2.00 | |
Potential % | 546.67 | Finscreener Ranking | — - | |
Insiders Trans % 3/6/12 mo. | -71/-89/-93 | Value Ranking | ★★★★ 56.24 | |
Insiders Value % 3/6/12 mo. | 71/-19/-53 | Growth Ranking | ★★★★+ 62.87 | |
Insiders Shares Cnt. % 3/6/12 mo. | 67/7/-14 | Income Ranking | — - | |
Price Range Ratio 52W % | 2.04 | Earnings Rating | — | |
Market Cap | 55.57M | Earnings Date | 2nd Nov 2023 | |
Alpha | 0.00 | Standard Deviation | 0.41 | |
Beta | 2.23 |
Today's Price Range 1.621.69 | 52W Range 1.556.44 |
Summary:
Sell
Technical Indicators: | Sell |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -8.84% | ||
1 Month | -30.38% | ||
3 Months | -28.88% | ||
6 Months | -49.23% | ||
1 Year | -59.91% | ||
3 Years | -84.76% | ||
5 Years | -91.82% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -36.67 | |||
ROE last 12 Months | -56.28 | |||
ROA (5Y Avg) | -9.89 | |||
ROA last 12 Months | -49.36 | |||
ROC (5Y Avg) | -25.67 | |||
ROC last 12 Months | -52.51 | |||
Return on invested Capital Q | -15.33 | |||
Return on invested Capital Y | -10.49 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 1.40 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-0.60 | ||||
0.42 | ||||
5.72 | ||||
- | ||||
-0.90 | ||||
-3.23 | ||||
0.42 | ||||
5.13 | ||||
-60 989 700.00 | ||||
Forward PE | - | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
9.10 | ||||
9.50 | ||||
0.12 | ||||
0.15 | ||||
-73.90 | ||||
Leverage Ratio | 1.20 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
7.70 | ||||
-787.30 | ||||
-762.00 | ||||
- | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
11.52M | ||||
0.38 | ||||
64.59 | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2023 | -0.95 | -0.99 | -4.21 |
Q01 2023 | -0.90 | -1.02 | -13.33 |
Q04 2022 | -0.96 | -0.93 | 3.12 |
Q03 2022 | -0.99 | -0.96 | 3.03 |
Q02 2022 | -1.02 | -0.99 | 2.94 |
Q01 2022 | -0.85 | -1.01 | -18.82 |
Q04 2021 | -0.73 | -0.88 | -20.55 |
Q03 2021 | -0.65 | -0.68 | -4.62 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
Next Report Date | 2nd Nov 2023 |
Estimated EPS Next Report | -0.68 |
Estimates Count | 1 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 125.71K |
Shares Outstanding | 33.68K |
Shares Float | 28.69M |
Trades Count | 704 |
Dollar Volume | 206.68K |
Avg. Volume | 235.37K |
Avg. Weekly Volume | 238.90K |
Avg. Monthly Volume | 204.69K |
Avg. Quarterly Volume | 262.52K |
DermTech Inc (NASDAQ: DMTK) stock closed at 1.65 per share at the end of the most recent trading day (a -2.94% change compared to the prior day closing price) with a volume of 125.71K shares and market capitalization of 55.57M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 64 people. DermTech Inc CEO is John D Dobak.
The one-year performance of DermTech Inc stock is -59.91%, while year-to-date (YTD) performance is -6.78%. DMTK stock has a five-year performance of -91.82%. Its 52-week range is between 1.55 and 6.44, which gives DMTK stock a 52-week price range ratio of 2.04%
DermTech Inc currently has a PE ratio of -0.60, a price-to-book (PB) ratio of 0.42, a price-to-sale (PS) ratio of 5.72, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -49.36%, a ROC of -52.51% and a ROE of -56.28%. The company’s profit margin is -%, its EBITDA margin is -762.00%, and its revenue ttm is $11.52 Million , which makes it $0.38 revenue per share.
Of the last four earnings reports from DermTech Inc, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.68 for the next earnings report. DermTech Inc’s next earnings report date is 02nd Nov 2023.
The consensus rating of Wall Street analysts for DermTech Inc is Moderate Buy (2), with a target price of $10.67, which is +546.67% compared to the current price. The earnings rating for DermTech Inc stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
DermTech Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
DermTech Inc has a Sell technical analysis rating based on Technical Indicators (ADX : 30.90, ATR14 : 0.16, CCI20 : -114.56, Chaikin Money Flow : -0.18, MACD : -0.22, Money Flow Index : 12.87, ROC : -18.72, RSI : 30.13, STOCH (14,3) : 6.43, STOCH RSI : 0.28, UO : 35.83, Williams %R : -93.57), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of DermTech Inc in the last 12-months were: Akhavan Ramin (Sold 3 776 shares of value $9 553 ), Claudia Ibarra (Sold 12 955 shares of value $46 672 ), Dobak John (Sold 25 514 shares of value $102 340 ), Ibarra Claudia (Sold 20 519 shares of value $66 739 ), John D Dobak (Sold 25 514 shares of value $102 340 ), Kevin Sun (Sold 12 221 shares of value $48 662 ), Ramin Akhavan (Sold 17 278 shares of value $64 371 ), Sun Kevin M (Sold 8 253 shares of value $21 246 ), Todd Michael Wood (Sold 10 114 shares of value $38 999 ), Wood Todd (Sold 14 467 shares of value $50 345 ), Wood Todd Michael (Sold 5 342 shares of value $13 628 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
DermTech Inc is an emerging growth molecular diagnostic company. The company is engaged in marketing and developing novel non-invasive genomic tests to aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. While the company generates revenue through laboratory services.
CEO: John D Dobak
Telephone: +1 858 450-4222
Address: 11099 N. Torrey Pines Road, La Jolla 92037, CA, US
Number of employees: 64
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.